Dillon Cockrell, Medical Assistant Professor of Oncology at Duke Cancer Center, shared a post on LinkedIn:
“Today is October 1st, which means it’s officially ESMO 2025 month. I’ll be sharing insights into the GU oncology studies I’m most looking forward to, starting with prostate cancer.
In recent decades, intensification strategies – doublets, triplets, biomarker-driven targets, SBRT, and most recently radioligand therapies – have transformed outcomes in metastatic prostate cancer.
The next wave is here: radioligand therapy moving earlier, alongside more personalized targeted inhibitors and novel immunotherapy approaches.
Here are a few abstracts I’ll be watching closely:
LBA6 – PSM Addition: 177Lu-PSMA-617 + ADT + ARPI in mHSPC.
- Already announced by Novartis as positive for rPFS with an OS trend. Expectations are this could bring radioligand therapy up front in mHSPC.
- The excitement is real, but so is the challenge: how do we ensure patients outside major academic centers can access this therapy?
- New pathways are sorely needed to prevent huge discrepancies in care for rural patients.
LBA89 – CCTG PR.21: 177Lu-PSMA-617 vs docetaxel in mCRPC.
- A rare head-to-head comparison that may inform both efficacy and quality-of-life tradeoffs, guiding an important clinical decision for both oncologists and patients.
2385MO – Pasritamig, JNJ-78278343: Translational T-cell analyses from a novel bispecific T cell engager in mCRPC.
- Are bispecific therapies finally the answer to unlocking IO utility in prostate cancer?
- Building on promising phase I activity and safety data presented at ASCO2025.
- Insights into which immune ‘fingerprints’ correlate with benefit – a step toward better combinations.
2383O – CAPItello-281: Capivasertib + abiraterone + ADT in PTEN-deficient mHSPC.
- Already flagged as positive for rPFS by AstraZeneca, bringing the first AKT inhibitor into the space.
- Will capi/abi for PTEN-deficient mHSPC parallel PARP inhibitor strategies (i.e. AMPLITUDE) in BRCA-mutant disease? Questions will similarly remain regarding long-term toxicity and comparison with triplet chemo.
- More support for upfront genomic testing at time of dx for all metastatic patients.
LBA86 – ENZARAD: Enzalutamide + ADT + RT in high-risk localized disease.
- If positive, enzalutamide could join abiraterone as a data-supported intensification strategy in definitive therapy.
Which of these abstracts do you think will most change our clinical practice? And what can we do to prepare for the real-world rollout of radioligand therapy in HSPC?”
More posts featuring Dillon Cockrell.